R&D
Advanced biopharmaceutical development company
Immune Cell
Immunity is a system that protects the body from foreign substances or self-derived substances,
and removes foreign substances, obtains acquired immunity through this,
and helps to maintain a healthy body by removing cancer cells.
When the immune system does not function normally, chronic infectious diseases or cancer occur, and when the immune system is out of balance, allergies or autoimmune diseases occur. Immune cells include macrophages, NK cells involved in innate immunity,
T cells and B cells involved in acquired immunity, and dendritic cells and gamma delta T cells involved in all types of immunity.
Among these immune cells, our company is developing NK cells as the main target, and we are performing a mass-culturing process of NK cells by using an advanced culture method using cell-derived additives such as cytokines, rather than a culture method using cancer antigens.
In addition, we are striving to develop more effective advanced biopharmaceuticals by converging NK cells and cytomaterial-related technologies obtained through this process.
Among these immune cells, our company is developing NK cells as the main target, and we are performing a mass-culturing process of NK cells by using an advanced culture method using cell-derived additives such as cytokines, rather than a culture method using cancer antigens.
In addition, we are striving to develop more effective advanced biopharmaceuticals by converging NK cells and cytomaterial-related technologies obtained through this process.
-
Cancer Cells-Feeder
Use of cancer cells
- - Difficult to remove cancer cells
- - Potential risk of residual cancer cells
- - Unsuitable for the establishment of mass production process
-
PBMCs-Feeder
Use of T cells in PBMC
- - Requirement of a lot of blood burdens patients
- - Inhibition of T cell proliferation - radiation equipment required
- - Need to follow up on residual T cells
-
Feeder-free Cytokine Cocktail
NK cell activation cytokine
- - Can be mass produced with little blood
- - Solves the problems of the existing technology
- - Requires optimal cytokine combination
Advanced Biopharmaceuticals
MYTO NK™
MYTO NK, an immune cell therapy under development by our company, is an anticancer drug that targets non-small cell lung cancer or liver cancer.
Lung cancer and liver cancer are known to be very prevalent in both men and women among cancer incidence rates in Korea.
MYTO NK is a treatment using NK cells and Cytomaterials, and has a superior apoptosis effect on cancer cells than existing NK cell treatments.
MYTO NK is a treatment using NK cells and Cytomaterials, and has a superior apoptosis effect on cancer cells than existing NK cell treatments.
